High-grade carcinoma with neuroendocrine differentiation of the urinary bladder: A case report of a rare variant
Neuroendocrine bladder carcinoma is considered a rare variant (<1%) with highly aggressive potential. Because of the rarity of its presentation, available data are mainly from published case reports. A 40-year-old male presented with painless hematuria for the past 3 months. After evaluation, he...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2022-01-01
|
| Series: | Annals of Oncology Research and Therapy |
| Subjects: | |
| Online Access: | http://www.aort.info/article.asp?issn=2772-8382;year=2022;volume=2;issue=2;spage=104;epage=106;aulast=Bansal |
| _version_ | 1797225848818892800 |
|---|---|
| author | Shashank Bansal Prutha Jinwala Aditya Elhence S P Shrivastava Vikas Asati Rajesh Patidar Prakash G Chitalkar |
| author_facet | Shashank Bansal Prutha Jinwala Aditya Elhence S P Shrivastava Vikas Asati Rajesh Patidar Prakash G Chitalkar |
| author_sort | Shashank Bansal |
| collection | DOAJ |
| description | Neuroendocrine bladder carcinoma is considered a rare variant (<1%) with highly aggressive potential. Because of the rarity of its presentation, available data are mainly from published case reports. A 40-year-old male presented with painless hematuria for the past 3 months. After evaluation, he underwent radical cystectomy with pelvic lymph node dissection with urinary diversion. Histopathology from the postoperative specimen was suggestive of high-grade carcinoma with neuroendocrine differentiation (CK-focal positive, synaptophysin-focal positive, GATA-3, CD-56 positive and Ki-67 85%–90% chromogranin A-negative) stage pT4bN2M0. The case was discussed in the multidisciplinary tumor board and was planned for adjuvant chemotherapy with cisplatin (75 mg/m2) and etoposide (100 mg/m2) Repeated every 21 days. He completed six cycles of adjuvant chemotherapy and was on follow-up. Within 3 months of completing adjuvant therapy, he presented again with a complaint of hematuria and on evaluation found to have a localized recurrence, following which he received radical chemoradiotherapy and is now on follow-up. Our case provides evidence to think us in new dimension, with chemotherapy in adjuvant and radiation in salvage settings instead of adjuvant settings. |
| first_indexed | 2024-03-07T21:36:58Z |
| format | Article |
| id | doaj.art-ccd22836f80b46b6ad615b3f4887d35e |
| institution | Directory Open Access Journal |
| issn | 2772-8382 2772-8390 |
| language | English |
| last_indexed | 2024-04-24T14:15:32Z |
| publishDate | 2022-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Annals of Oncology Research and Therapy |
| spelling | doaj.art-ccd22836f80b46b6ad615b3f4887d35e2024-04-03T08:46:28ZengWolters Kluwer Medknow PublicationsAnnals of Oncology Research and Therapy2772-83822772-83902022-01-012210410610.4103/aort.aort_20_22High-grade carcinoma with neuroendocrine differentiation of the urinary bladder: A case report of a rare variantShashank BansalPrutha JinwalaAditya ElhenceS P ShrivastavaVikas AsatiRajesh PatidarPrakash G ChitalkarNeuroendocrine bladder carcinoma is considered a rare variant (<1%) with highly aggressive potential. Because of the rarity of its presentation, available data are mainly from published case reports. A 40-year-old male presented with painless hematuria for the past 3 months. After evaluation, he underwent radical cystectomy with pelvic lymph node dissection with urinary diversion. Histopathology from the postoperative specimen was suggestive of high-grade carcinoma with neuroendocrine differentiation (CK-focal positive, synaptophysin-focal positive, GATA-3, CD-56 positive and Ki-67 85%–90% chromogranin A-negative) stage pT4bN2M0. The case was discussed in the multidisciplinary tumor board and was planned for adjuvant chemotherapy with cisplatin (75 mg/m2) and etoposide (100 mg/m2) Repeated every 21 days. He completed six cycles of adjuvant chemotherapy and was on follow-up. Within 3 months of completing adjuvant therapy, he presented again with a complaint of hematuria and on evaluation found to have a localized recurrence, following which he received radical chemoradiotherapy and is now on follow-up. Our case provides evidence to think us in new dimension, with chemotherapy in adjuvant and radiation in salvage settings instead of adjuvant settings.http://www.aort.info/article.asp?issn=2772-8382;year=2022;volume=2;issue=2;spage=104;epage=106;aulast=Bansalchemoradiotherapyneuroendocrine carcinomaurinary bladder cancer |
| spellingShingle | Shashank Bansal Prutha Jinwala Aditya Elhence S P Shrivastava Vikas Asati Rajesh Patidar Prakash G Chitalkar High-grade carcinoma with neuroendocrine differentiation of the urinary bladder: A case report of a rare variant Annals of Oncology Research and Therapy chemoradiotherapy neuroendocrine carcinoma urinary bladder cancer |
| title | High-grade carcinoma with neuroendocrine differentiation of the urinary bladder: A case report of a rare variant |
| title_full | High-grade carcinoma with neuroendocrine differentiation of the urinary bladder: A case report of a rare variant |
| title_fullStr | High-grade carcinoma with neuroendocrine differentiation of the urinary bladder: A case report of a rare variant |
| title_full_unstemmed | High-grade carcinoma with neuroendocrine differentiation of the urinary bladder: A case report of a rare variant |
| title_short | High-grade carcinoma with neuroendocrine differentiation of the urinary bladder: A case report of a rare variant |
| title_sort | high grade carcinoma with neuroendocrine differentiation of the urinary bladder a case report of a rare variant |
| topic | chemoradiotherapy neuroendocrine carcinoma urinary bladder cancer |
| url | http://www.aort.info/article.asp?issn=2772-8382;year=2022;volume=2;issue=2;spage=104;epage=106;aulast=Bansal |
| work_keys_str_mv | AT shashankbansal highgradecarcinomawithneuroendocrinedifferentiationoftheurinarybladderacasereportofararevariant AT pruthajinwala highgradecarcinomawithneuroendocrinedifferentiationoftheurinarybladderacasereportofararevariant AT adityaelhence highgradecarcinomawithneuroendocrinedifferentiationoftheurinarybladderacasereportofararevariant AT spshrivastava highgradecarcinomawithneuroendocrinedifferentiationoftheurinarybladderacasereportofararevariant AT vikasasati highgradecarcinomawithneuroendocrinedifferentiationoftheurinarybladderacasereportofararevariant AT rajeshpatidar highgradecarcinomawithneuroendocrinedifferentiationoftheurinarybladderacasereportofararevariant AT prakashgchitalkar highgradecarcinomawithneuroendocrinedifferentiationoftheurinarybladderacasereportofararevariant |